Walter Alexander


Authored Items

Adding Radiation to First-Line FOLFOX Reduces Liver Metastases Progression in Patients with Metastatic Colorectal Cancer

June 2015, Vol 6, No 5 - ASCO 2015 Highlights

Chicago, IL—In patients with metastatic colorectal cancer (mCRC) with liver-dominant metastases who received first-line FOLFOX (leucovorin, fluorouracil [Adrucil], and oxaliplatin [Eloxatin]) with or without bevacizumab (Avastin) plus selective internal radiation therapy (SIRT) compared with FOLFOX with or without bevacizumab, progression-free survival (PFS) in the liver was extended by 7.9 months, according to the results of the SIRFLOX trial, which were presented at the 2015 American Society of Clinical Oncology (ASCO) meeting. [ Read More ]

Ramucirumab Confers Survival Benefit in Some Patients with Hepatocellular Carcinoma

November 2015, Vol 6, No 10 - GI Cancers

Barcelona, Spain—In the REACH trial evaluating ramucirumab (Cyramza) as second-line treatment in patients with advanced hepatocellular carcinoma after first-line therapy with sorafenib (Nexavar), overall survival (OS) was improved in the subgroup population with baseline α-fetoprotein of ?400 ng/mL (Child-Pugh class A). The OS benefits in the overall population (Child-Pugh classes A and B) did not reach significance, said lead investigator Andrew X. Zhu, MD, PhD, Massachusetts General Hospital Cancer Center, Boston. [ Read More ]

Systemic Therapy plus Radiofrequency: Ablation Survival Benefit in Colorectal Liver Metastases

November 2015, Vol 6, No 10 - GI Cancers

Barcelona, Spain—The first randomized study prospectively investigating the efficacy of radiofrequency ablation (RFA) added to standard systemic treatment in patients with unresectable colo­rectal cancer (CRC) liver metastases revealed progression-free survival (PFS) and overall survival (OS) benefits, according to Theo J.M. Ruers, MD, PhD, Department of Surgery, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Ziekenhuis, Amsterdam. [ Read More ]

Aprepitant Improves Emesis Control in Patients with Colorectal Cancer

November 2015, Vol 6, No 10 - GI Cancers

Barcelona, Spain—Controlling and minimizing nausea and vomiting enables patients with cancer to continue their chemotherapy. A clinical trial reported at the 2015 European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer shows that the newly approved agent aprepitant (Emend), an oral neurokinin (NK)1 antagonist, improved antiemetic control in patients with colorectal cancer (CRC) who were receiving oxaliplatin-based chemotherapy, according to Junichi Nishimura, MD, Assistant Professor, Osaka University, Japan. [ Read More ]

Combination Immunotherapy the New Standard for Patients with Metastatic Melanoma

June 2016, Vol 7, No 5 - Melanoma

The key arguments supporting the use of combination therapy with checkpoint blockade immunotherapies as the standard of care for treating metastatic melanoma arise from the combination’s high disease control rates; rapid deep responses; improved response rates; longer progression-free survival (PFS); and good estimated overall survival (OS), approaching 70% at 3 years, said Steven J. O’Day, MD, Professor of Medical Oncology, John Wayne Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA, at the recent HemOnc Today Melanoma and Cutaneous Malignancies meeting. [ Read More ]

Concurrent Radiation and Temozolomide Lowers Risk for Death in Elderly Patients with Glioblastoma

September 2016, Vol 7, No 8 - Brain Cancer

The first study to assess the addition of temozolomide (Temodar) chemotherapy during short-course radiation therapy, followed by monthly maintenance of temozolomide in elderly patients with glioblastoma showed a significantly reduced risk for death, said the study co-author James R. Perry, MD, FRCPC, The Crolla Family Endowed Chair in Brain Tumour Research, Odette Cancer and Sunnybrook Health Sciences Centres, Toronto, Canada, in a plenary session at the 2016 American Society of Clinical Oncology annual meeting. [ Read More ]

Adding Capecitabine to Gemcitabine Chemotherapy After Pancreatic Cancer Surgery Improves Survival

September 2016, Vol 7, No 8 - Pancreatic Cancer

Adding capecitabine chemotherapy to gemcitabine after pancreatic cancer resection was associated with longer overall survival (OS) than gemcitabine chemotherapy alone, according to results from the European Study Group for Pancreatic Cancer (ESPAC)-4 clinical trial. For the small proportion of patients with pancreatic cancer who are candidates for surgery, adjuvant gemcitabine chemotherapy is the current standard of care worldwide, said John P. Neoptolemos, MD, Chair of Surgery, University of Liverpool, United Kingdom, during an oral abstract session at the 2016 American Society of Clinical Oncology annual meeting. “We thought that the combination of gemcitabine plus capecitabine…may be better than gemcitabine alone, and launched the phase 3 ESPAC-4 trial,” he stated. [ Read More ]

Lenalidomide Maintenance Therapy After ASCT Shows Survival Benefit in Patients with Multiple Myeloma

September 2016, Vol 7, No 8 - Hematologic Cancers

A meta-analysis of overall survival (OS) in 3 clinical trials of lenalidomide (Revlimid) maintenance therapy after high-dose melphalan (Alkeran) and autologous stem-cell transplantation (ASCT) for multiple myeloma showed long-term disease control and prolonged OS. A slightly increased risk for a secondary primary malignancy is outweighed by the OS benefit, said lead investigator Philip McCarthy, MD, Roswell Park Cancer Institute, Buffalo, NY, in an oral presentation at the 2016 American Society of Clinical Oncology annual meeting. [ Read More ]

HF10 plus Ipilimumab Increases Response Rates in Metastatic Melanoma

September 2016, Vol 7, No 8 - Melanoma

When combined with systemic ipilimumab (Yervoy), the investigational oncolytic viral immunotherapy HF10, a mutation of the HF strain of the herpes simplex virus type 1 (HSV-1), has local and systemic activity in patients with metastatic melanoma, said Robert Andtbacka, MD, CM, Huntsman Cancer Institute, Salt Lake City, during a poster presentation at the 2016 American Society of Clinical Oncology meeting. He added that HF10 substantially improves the response rate of ipilimumab alone and does not exacerbate ipilimumab toxicity. [ Read More ]

Urelumab Safe and Active as Monotherapy and in Combination with Nivolumab in Several Types of Cancer

April 2017, Vol 8, No 2 - Immunotherapy

National Harbor, MD—The investigational CD137 agonist urelumab, given as monotherapy and in combination with the anti–PD-1 monoclonal antibody nivolumab, demonstrated safety and, in some patients with hematologic and solid tumor malignancies, promising antitumor activity, according to results of 2 early-phase studies presented at the 2016 Society for Immunotherapy of Cancer annual meeting. [ Read More ]

Immunotherapy with Nivolumab plus Ipilimumab Improves Outcomes in Metastatic Urothelial Cancer

April 2017, Vol 8, No 2 - Immunotherapy

National Harbor, MD—Results of a phase 1/2 study that investigated 2 dosing regi­mens of 2 immunotherapies—the PD-1 inhibitor nivolumab (Opdivo) plus the CTLA-4 inhibitor ipilimumab (Yervoy)—in patients with previously treated metastatic urothelial carcinoma showed higher response rates and longer median overall survival with the regimen of nivolumab 1 mg/kg plus ipilimumab 3 mg/kg than with the dosing of nivolu­mab 3 mg/kg plus ipilimumab 1 mg/kg. [ Read More ]

PV-10 Therapy Shows Promise for Hepatic Tumors

June 2017, Vol 8, No 3 - Emerging Therapies

Hollywood, FL—A basket study of the oncolytic immunotherapy PV-10 (10% Rose Bengal disodium for injection), which included patients with tumors originating in various locations, showed that data for gastrointestinal lesions were especially encouraging, reported Paul M. Goldfarb, MD, FACS, a surgeon at Oncology Associates of San Diego, CA, at the 2017 Clinical Interventional Oncology annual symposium. [ Read More ]